S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Global markets are mixed as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
Biden administration agrees to provide $6.4 billion to Samsung for making computer chips in Texas
The IRS is quicker to answer the phone on this Tax Day
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Global markets are mixed as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
Biden administration agrees to provide $6.4 billion to Samsung for making computer chips in Texas
The IRS is quicker to answer the phone on this Tax Day
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Global markets are mixed as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
Biden administration agrees to provide $6.4 billion to Samsung for making computer chips in Texas
The IRS is quicker to answer the phone on this Tax Day
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Divisive? Not for moviegoers. ‘Civil War’ declares victory at box office.
Stock market today: Global markets are mixed as Middle East tensions escalate
Native American-led nonprofit says it bought 40 acres in the Black Hills of South Dakota
Tax Day reveals a major split in how Joe Biden and Donald Trump would govern
Biden administration agrees to provide $6.4 billion to Samsung for making computer chips in Texas
The IRS is quicker to answer the phone on this Tax Day
NASDAQ:CDNA

CareDx (CDNA) Stock Price, News & Analysis

$8.53
-0.61 (-6.67%)
(As of 04/12/2024 08:51 PM ET)
Today's Range
$8.46
$9.14
50-Day Range
$7.96
$12.08
52-Week Range
$4.80
$12.93
Volume
726,100 shs
Average Volume
914,480 shs
Market Capitalization
$441.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

CareDx MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
29.0% Upside
$11.00 Price Target
Short Interest
Bearish
10.48% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.66
Upright™ Environmental Score
News Sentiment
0.74mentions of CareDx in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.59) to ($1.17) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.20 out of 5 stars

Medical Sector

310th out of 928 stocks

Medical Laboratories Industry

10th out of 19 stocks

CDNA stock logo

About CareDx Stock (NASDAQ:CDNA)

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

CDNA Stock Price History

CDNA Stock News Headlines

Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
CDNA Apr 2024 10.000 put
CDNA Apr 2024 2.500 call
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
CDNA Mar 2024 17.500 call
CareDx, Inc (NASDAQ:CDNA) Q4 2023 Earnings Call Transcript
Earnings Outlook For CareDx
CareDx Stock (NASDAQ:CDNA), Short Interest Report
CDNA Mar 2024 7.500 put
CDNA Mar 2024 12.500 call
H.C. Wainwright Keeps Their Hold Rating on CareDx (CDNA)
See More Headlines
Receive CDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CareDx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/14/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:CDNA
Employees
635
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.00
High Stock Price Target
$12.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+29.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-190,280,000.00
Pretax Margin
-67.83%

Debt

Sales & Book Value

Annual Sales
$280.32 million
Book Value
$4.83 per share

Miscellaneous

Free Float
49,604,000
Market Cap
$441.68 million
Optionable
Optionable
Beta
1.42
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Mr. Abhishek Jain (Age 47)
    CFO & Principal Accounting Officer
    Comp: $425.58k
  • Dr. Peter Maag Ph.D. (Age 57)
    Executive Director
    Comp: $43.23k
  • Mr. Alexander L. Johnson (Age 50)
    President of Patient & Testing Services
    Comp: $547.43k
  • Ms. Marica Grskovic Ph.D.
    Chief Operating Officer
  • Dr. Robert N. Woodward Ph.D.
    Chief Scientific Officer
  • Mr. GS Jha
    Senior VP, Chief Information Officer & Chief Information Security Officer
  • Mr. Ian Cooney
    Vice President of Investor Relations
  • Jeffrey A. Novack
    General Counsel
  • Ms. Stacey Follon
    Senior VP & Head of Human Resources
  • Mr. Kashif Rathore
    Chief of Patient & Digital Solutions

CDNA Stock Analysis - Frequently Asked Questions

Should I buy or sell CareDx stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CDNA shares.
View CDNA analyst ratings
or view top-rated stocks.

What is CareDx's stock price target for 2024?

4 Wall Street analysts have issued 1-year price objectives for CareDx's shares. Their CDNA share price targets range from $10.00 to $12.00. On average, they predict the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 29.0% from the stock's current price.
View analysts price targets for CDNA
or view top-rated stocks among Wall Street analysts.

How have CDNA shares performed in 2024?

CareDx's stock was trading at $12.00 at the start of the year. Since then, CDNA stock has decreased by 28.9% and is now trading at $8.53.
View the best growth stocks for 2024 here
.

When is CareDx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our CDNA earnings forecast
.

How were CareDx's earnings last quarter?

CareDx, Inc (NASDAQ:CDNA) issued its quarterly earnings data on Wednesday, February, 28th. The company reported ($2.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by $1.97. The company had revenue of $65.57 million for the quarter, compared to the consensus estimate of $63.66 million. CareDx had a negative trailing twelve-month return on equity of 51.40% and a negative net margin of 67.88%. CareDx's revenue for the quarter was down 20.4% compared to the same quarter last year. During the same period last year, the business earned ($0.34) EPS.

What guidance has CareDx issued on next quarter's earnings?

CareDx issued an update on its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $260.0 million-$274.0 million, compared to the consensus revenue estimate of $260.6 million.

What other stocks do shareholders of CareDx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CareDx investors own include Block (SQ), Roku (ROKU), Exact Sciences (EXAS), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Enphase Energy (ENPH), Johnson & Johnson (JNJ), Activision Blizzard (ATVI) and Alibaba Group (BABA).

Who are CareDx's major shareholders?

CareDx's stock is owned by a number of retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.50%). Insiders that own company stock include Ankur Dhingra, George Bickerstaff, Grace Colon, Michael Goldberg, Paul Adler, Peter Maag, Ralph Snyderman, Reginald Seeto, Sasha King, Thomas A Thomas and William A Hagstrom.
View institutional ownership trends
.

How do I buy shares of CareDx?

Shares of CDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CDNA) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners